Current Treatment Options in Dry Eye Disease
sponsored by Santen
Managing dry eye disease becomes disproportionately more difficult as the severity of the disease increases: artificial tears and lubricants are not enough to help patients with severe dry eye disease. So what’s currently on offer?
The management of patients with mild-to-moderate dry eye disease (DED) is relatively simple (1): symptom control with artificial tears and lubricants. However, once DED starts to become classified as severe, it becomes much harder to control; you need to address not just the symptoms, but also the cause: inflammation.
Dampening the inflammation present in the ocular surface of patients with severe dry eye is key to achieving better outcomes. If we refer to Figure 1 – the vicious circle theory of dry eye – artificial tears and lubricants can help address the dry eye symptoms caused by the factors on the outside of the vicious circle, but they do nothing to address the disease processes at its core. Anti-inflammatory agents can get inside the vicious circle and disrupt it, resulting in a therapy that addresses the causes of DED, not just the symptoms (2).
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.